The Chemours Company (CC) investor relations material

Executive summary

• Net sales reached $1.4 billion in Q1 2026, up 1% year-over-year, driven by strong TSS and TT segment performance and price/currency gains despite lower volumes.

• Net loss widened to $29 million, mainly due to higher financing, SG&A, and legal costs.

• Adjusted EBITDA was $169 million, up 2% year-over-year, with TSS strength offsetting TT and APM declines.

• Completed $700 million senior unsecured notes offering and received $287 million from Kuan Yin site sale, enhancing balance sheet flexibility.

• Significant progress on operational reliability, cost discipline, and strategic initiatives, including Lean principles and restructuring.

Financial highlights

• Net sales: $1,381 million (+1% YoY, +4% sequentially); Adjusted EBITDA: $169 million (+2% YoY); net loss: $29 million.

• Free cash flow usage improved to $93 million from $196 million YoY; capex decreased to $49 million from $84 million YoY.

• Adjusted net income was $8 million ($0.05 per share), down from $19 million ($0.13 per share) year-over-year.

• Gross profit declined to $212 million from $236 million year-over-year; gross margin 15.3%.

• Interest expense increased to $69 million, reflecting higher rates and new debt issuance.

Outlook and guidance

• Q2 2026 net sales expected to rise 15–20% sequentially; adjusted EBITDA forecasted at $220–$250 million.

• Full-year 2026 net sales projected to grow 3–5% over 2025, with adjusted EBITDA between $800–$900 million.

• Capital expenditures for 2026 anticipated at $275–$325 million; free cash flow conversion above 20%.

• Net leverage ratio targeted below 3.8x by year-end 2026.

• Management expects sufficient liquidity through at least May 2027, with $563 million in cash and $953 million available under the revolver.